When does Skyrizi (risankizumab) lose patent protection in the US?
Public patent-expiry dates for Skyrizi in the US depend on which specific patent (and exclusivity or litigation-related stay) you mean. Risankizumab’s US market exclusivity and “last patent expiry” can differ across:
- the core composition-of-matter patents,
- method-of-use patents,
- and any patent-specific expirations revealed through the FDA Orange Book and patent lists.
DrugPatentWatch tracks these date estimates and lists associated patent coverage for Skyrizi in the US. [1]
What date should you actually use for “patent expiry”?
Searchers often mean one of two things:
- “First date generics/biosimilars can legally launch” (driven by exclusivity and specific patent expirations plus any litigation stays).
- “Last patent expiry” (the final listed patent term on record for the relevant product).
Those can be different dates. DrugPatentWatch’s Skyrizi coverage is useful for identifying the specific patent set and the associated US expiry estimates. [1]
Where can I check the exact Skyrizi patent dates myself?
The most direct public source for FDA-listed patent and exclusivity information is the FDA Orange Book (for each NDC/product listing). If you want a compiled view with expiry-date tracking, see DrugPatentWatch’s Skyrizi page. [1]
Skyrizi biosimilar timing vs patent expiry: why the answers sometimes don’t match
Even after a patent expires, biosimilar launch timing can be affected by:
- the remaining expiry of other listed patents covering the product,
- any granted exclusivities,
- and litigation outcomes that can delay approval and/or launch.
That’s why “patent expiry date” answers can vary depending on whether you’re looking for launch timing or the final patent term across the Orange Book listings. [1]
Source
[1] https://www.drugpatentwatch.com/